Anti-Diabetes Drugs - Uganda

Uganda

In Uganda, the projected revenue in the Anti-Diabetes Drugs market is expected to reach US$24.58m in 2024.
This revenue is forecasted to exhibit an annual growth rate (CAGR 2024-2028) of 5.14%, leading to a market volume of US$30.04m by 2028.
When compared globally, United States is anticipated to generate the highest revenue, reaching US$35,630.00m in 2024.
The demand for anti-diabetes drugs in Uganda is rising steadily due to the increasing prevalence of diabetes among the population.

Key regions: India, Canada, Australia, France, Italy

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Diabetes Drugs market in Uganda has been experiencing steady growth in recent years.

Customer preferences: Uganda has a high prevalence of diabetes, particularly among the elderly population. As a result, there is a high demand for anti-diabetes drugs in the country. Patients tend to prefer drugs that are affordable and effective, with minimal side effects.

Trends in the market: The market for anti-diabetes drugs in Uganda is dominated by big pharmaceutical companies that offer a wide range of products. There has been a recent trend towards the use of generic drugs, which are more affordable for patients. In addition, there has been an increase in the availability of over-the-counter anti-diabetes drugs, which has made it easier for patients to access medication.

Local special circumstances: One of the challenges facing the anti-diabetes drugs market in Uganda is the lack of access to healthcare in rural areas. Many patients in these areas do not have access to medication or healthcare facilities, which has led to a high rate of undiagnosed diabetes cases. In addition, there is a lack of awareness about diabetes and its complications, which has contributed to the high prevalence of the disease.

Underlying macroeconomic factors: Uganda's economy has been growing steadily in recent years, which has led to an increase in disposable income among the population. This has made it easier for patients to afford medication and healthcare services. In addition, the government has been investing in healthcare infrastructure and increasing access to healthcare services, which has contributed to the growth of the anti-diabetes drugs market. However, the country still faces challenges such as a high poverty rate and a lack of access to healthcare in rural areas, which could impact the growth of the market in the future.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.